Study of ATH434 in Participants with Multiple System Atrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

November 28, 2024

Study Completion Date

November 28, 2024

Conditions
Multiple System Atrophy
Interventions
DRUG

ATH434 dose level 1

ATH434 taken BID

DRUG

ATH434 dose level 2

ATH434 taken BID

DRUG

Placebo

Placebo taken BID

Trial Locations (23)

10032

Columbia University Irving Medical Center, New York

13005

CHU de Marseille/Hôpital de la Timone, Marseille

21287

Johns Hopkins University, Baltimore

31059

CHU de Toulouse/Hôpital Pierre-Paul Riquet, Toulouse

33076

CHU de Bordeaux/Groupe Hospitalier Pellegrin, Bordeaux

37232

Vanderbilt University Medical Center, Nashville

60612

Rush University Medical Center, Chicago

74136

The Movement Disorder Clinic of Oklahoma, Tulsa

75013

CHU/HU Pitié Salpêtrière, Paris

92093

University of California San Diego, La Jolla

Unknown

St Vincent's Hospital (Sydney), Darlinghurst

Westmead Hospital, Westmead

The Alfred Hospital, Melbourne

IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna

Policlinico di Milano, Milan

Azienda Ospedaliero-Universitaria Pisana, Pisa

AOU San Giovanni di Dio Ruggi d'Aragona, Salerno

New Zealand Brain Research Institute, Christchurch

Auckland City Hospital, Grafton

University College London, London

Newcastle University, Newcastle upon Tyne

Salford Royal Hospital, Salford

Queen Elizabeth University Hospital, Glasgow

Sponsors
All Listed Sponsors
lead

Alterity Therapeutics

INDUSTRY

NCT05109091 - Study of ATH434 in Participants with Multiple System Atrophy | Biotech Hunter | Biotech Hunter